1. Epigenetics
    JAK/STAT Signaling
    Stem Cell/Wnt
  2. JAK
  3. JAK Inhibitors

JAK Inhibitors

JAK1

JAK2

JAK3

Tyk2

JAK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

JAK Inhibitors
Product Name JAK1 JAK2 JAK3 Tyk2 JAK Purity
Ruxolitinib
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
  99.99%
Tofacitinib
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
JAK3, IC50: 1 nM
    99.96%
Lestaurtinib  
JAK2, IC50: 0.9 nM
      >99.0%
Abrocitinib
JAK1, IC50: 29 nM
JAK2, IC50: 803 nM
 
Tyk2, IC50: 1253 nM
  99.79%
Fedratinib  
JAK2, IC50: 3 nM
JAK2(V617F), IC50: 3 nM
      98.62%
Momelotinib
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
    98.11%
CHZ868  
JAK2, IC50: 110 nM
      98.33%
AZD-1480
JAK1, IC50: 1.3 nM
JAK2, IC50: 0.4 nM
      99.37%
Filgotinib
JAK1, IC50: 10 nM
JAK2, IC50: 28 nM
JAK3, IC50: 810 nM
Tyk2, IC50: 116 nM
  99.64%
AT9283  
JAK2, IC50: 1.2 nM
JAK3, IC50: 1.1 nM
    99.13%
Itacitinib
JAK1
        99.87%
Tyk2-IN-4      
Tyk2
  99.76%
Gandotinib  
JAK2, IC50: 3 nM
JAK3, IC50: 48 nM
Tyk2, IC50: 44 nM
  99.96%
Cucurbitacin I  
JAK2
      >98.0%
Delgocitinib
JAK1, IC50: 2.8 nM
JAK2, IC50: 2.6 nM
JAK3, IC50: 13 nM
Tyk2, IC50: 58 nM
  99.14%
PF-06651600    
JAK3, IC50: 33.1 nM
    99.98%
Decernotinib
JAK1, Ki: 11 nM
JAK2, Ki: 13 nM
JAK3, Ki: 2.5 nM
Tyk2, Ki: 11 nM
  98.91%
TG101209  
JAK2, IC50: 6 nM
JAK3, IC50: 169 nM
    98.94%
CEP-33779  
JAK2, IC50: 1.8 nM
JAK3, IC50: 150 nM
    98.04%
Baricitinib phosphate
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
  99.49%
Oclacitinib maleate
JAK1, IC50: 10 nM
JAK2, IC50: 18 nM
JAK3, IC50: 99 nM
Tyk2, IC50: 84 nM
  99.53%
SAR-20347
JAK1, IC50: 23 nM
JAK2, IC50: 26 nM
JAK3, IC50: 41 nM
Tyk2, IC50: 0.6 nM
  97.00%
AZ960  
JAK2, Ki: 0.45 nM
JAK2, IC50: <3 nM
JAK3, IC50: 9 nM
    98.04%
TyK2-IN-2      
Tyk2
  99.41%
BMS-911543
JAK1, IC50: 75 nM
JAK2, IC50: 1.1 nM
JAK3, IC50: 360 nM
Tyk2, IC50: 66 nM
  98.12%
Ilginatinib
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  95.88%
Itacitinib adipate
JAK1
        99.37%
FM381    
JAK3, IC50: 127 pM
    98.41%
JANEX-1    
JAK3, IC50: 78 μM
    99.84%
ZM39923 hydrochloride
JAK1, pIC50: 4.4
 
JAK3, pIC50: 7.1
    >98.0%
NVP-BSK805 dihydrochloride
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
JAK3 JH1, IC50: 18.68 nM
TYK2 JH1, IC50: 10.76 nM
  99.36%
WHI-P154    
JAK3, IC50: 1.8 μM
    98.14%
WHI-P97    
JAK3, IC50: 11 μM
    99.48%
XL019  
JAK2, IC50: 2.2 nM
JAK3, IC50: 214.2 nM
    >98.0%
JAK3-IN-1
JAK1, IC50: 896 nM
JAK2, IC50: 1050 nM
JAK3, IC50: 4.8 nM
    99.98%
GLPG0634 analog    
JAK3, IC50: <100 nM
Tyk2, IC50: <100 nM
  98.00%
Ilginatinib hydrochloride
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  98.02%
Ilginatinib maleate
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  97.04%
JAK1-IN-3
JAK1, IC50: 73 nM
        99.32%
Protosappanin A  
JAK2
      98.88%
Momelotinib sulfate
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
    >96.0%
NSC 42834  
JAK2-WT, IC50: 15 μM
JAK2-V617F, IC50: 28 μM
      95.5%
NVP-BSK805
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
JAK3 JH1, IC50: 18.68 nM
TYK2 JH1, IC50: 10.76 nM
 
JAK1-IN-4
JAK1, IC50: 85 nM
JAK2, IC50: 12.8 μM
     
Tyk2-IN-5      
Tyk2 JH2, Ki: 0.086 nM
 
JAK-IN-4        
JAK
JAK-IN-3
JAK1, IC50: 5 nM
JAK2, IC50: 70 nM
JAK3, IC50: 3 nM
Tyk2, IC50: 34 nM
 
JAK3 covalent inhibitor-1    
JAK3, IC50: 11 nM
   
JAK3-IN-6    
JAK3, IC50: 0.15 nM
   
JAK/HDAC-IN-1
JAK1, IC50: 4.8 nM
JAK2, IC50: 4 nM
JAK3, IC50: 7.4 nM
Tyk2, IC50: 49 nM
 
BMS-066      
Tyk2, IC50: 72 nM
 
Momelotinib Mesylate
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
   
Ruxolitinib sulfate
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
 
ZM39923
JAK1, pIC50: 4.4
 
JAK3, pIC50: 7.1
   
JAK3-IN-7    
JAK3, IC50: 0.01 μM